Geburtshilfe Frauenheilkd 2013; 73(6): 556-583
Georg Thieme Verlag KG Stuttgart · New York
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy
and Follow-up Care of Breast Cancer
Short version – AWMF Registry No.: 032-045OL AWMF-Register-Nummer:
032-045OL – Kurzversion 3.0, Juli 2012 Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie
und Nachsorge des Mammakarzinoms
R. Kreienberg
1
Landshut
,
U.-S. Albert
2
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Klinik
für Gynäkologie, Gynäkologische Endokrinologie und Onkologie,
Marburg
,
M. Follmann
3
Deutsche Krebsgesellschaft e. V., Bereich Leitlinien,
Berlin
,
I. B. Kopp
4
AWMF-Institut für Medizinisches Wissensmanagement, c/o
Philipps-Universität, Marburg
,
T. Kühn
5
Klinikum Esslingen, Klinik für Frauenheilkunde und Geburtshilfe,
Esslingen
,
A. Wöckel
6
Universitätsklinikum Ulm, Klinik für Frauenheilkunde und Geburtshilfe,
Ulm
› Institutsangaben
8 References
1 Aberizk WJ, Silver B, Henderson IC et al. The use of radiotherapy for treatment of isolated locoregional recurrence of
breast carcinoma after mastectomy. Cancer 1986; 58: 1214-1218
2 Aguiar-Bujanda D, Bohn-Sarmiento U, Aguiar-Morales J. False elevation of serum CA 15–3 levels in patients under follow-up for breast
cancer. Breast J 2004; 10: 375-376
3 Ahn PH, Vu HT, Lannin D et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer
does not affect local relapse rates. J Clin Oncol 2005; 23: 17-23
4 Albert US, Schulz K, Alt D et al. Eine Leitlinie für Leitlinien: methodische Erstellung und Anwendung der
Leitlinie Fraueninformation. Zentralbl Gynaekol 2003; 125: 484-493
5 Albert US und die Mitglieder der Planungskommission und
Arbeitsgruppenleiter der Konzertierten Aktion Brustkrebs-Früherkennung in
Deutschland. Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland, 1. Aktualisierung
2008. München: Zuckschwerdt Verlag; 2008
6 Alderson PO, Adams DF, McNeil BJ et al. Computed tomography, ultrasound, and scintigraphy of the liver in patients with
colon or breast carcinoma: a prospective comparison. Radiology 1983; 149: 225-230
7 Ali SM, Harvey HA, Lipton A. Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res 2003; 1 (415 Suppl.) S132-S137
8 Amendoeira I. Quality Assurance Guidelines for Pathology: Open Biopsy and Resection
Specimens. In: Perry NM, ed. European Guidelines for Quality Assurance in Breast Cancer Screening and
Diagnosis. Luxemburg: Office for Official Publications of the European Communities; 2006: 256-311
9 Andersson M, Madsen EL, Overgaard M et al. Doxorubicin versus methotrexate both combined with cyclophosphamide,
5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast
cancer – a randomised study with more than 10 years follow-up from the Danish
Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group
(DBCG). Eur J Cancer 1999; 35: 39-46
10 Antonini N, Jones H, Horiot JC et al. Effect of age and radiation dose on local control after breast conserving
treatment: EORTC trial 22881–10882. Radiother Oncol 2007; 82: 265-271
11 Armer J, Fu MR, Wainstock JM et al. Lymphedema following breast cancer treatment, including sentinel lymph node
biopsy. Lymphology 2004; 37: 73-91
12 Azria D, Betz M, Bourgier C et al. Identifying patients at risk for late radiation-induced toxicity. Crit Rev Oncol Hematol 2012; 84 (Suppl. 01) e35-e41
13 Balduzzi A, Leonardi MC, Cardillo A et al. Timing of adjuvant systemic therapy and radiotherapy after breast-conserving
surgery and mastectomy. Cancer Treat Rev 2010; 36: 443-450
14 Bani HA, Fasching PA, Lux MM et al. Lymphedema in breast cancer survivors: assessment and information provision in a
specialized breast unit. Patient Educ Couns 2007; 66: 311-318
15 Bartelink H, Horiot JC, Poortmans PM et al. Impact of a higher radiation dose on local control and survival in
breast-conserving therapy of early breast cancer: 10-year results of the
randomized boost versus no boost EORTC22881–10882 trial. J Clin Oncol 2007; 25: 3259-3265
16 Bathe OF, Kaklamanos IG, Moffat FL et al. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary
and hepatic metastases from breast cancer. Surg Oncol 1999; 8: 35-42
17 Baxter NN, Virnig BA, Durham SB et al. Radiation after lumpectomy for DCIS to reduce the risk of invasive breast
cancer: a population-based study [Meeting Abstracts]. J Clin Oncol 2005; 23 (16 Suppl.) 516
18 Belkacemi Y, Fourquet A, Cutuli B et al. Radiotherapy for invasive breast cancer: guidelines for clinical practice from
the French expert review board of Nice/Saint-Paul de Vence. Crit Rev Oncol Hematol 2011; 79: 91-102
19 Belkacemi Y, Gligorov J, Ozsahin M et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer
patients: acute toxicity analyses from the French multicentric study. Ann Oncol 2008; 19: 1110-1116
20 Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a
systematic review. Int J Cancer 2007; 121: 225-231
21 Bijker N, Meijnen P, Peterse JL et al. Breast-conserving treatment with or without radiotherapy in ductal
carcinoma-in-situ: ten-year results of European Organisation for Research and
Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC
Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24: 3381-3387
22 Blichert-Toft M, Smola MG, Cataliotti L et al. Principles and guidelines for surgeons – management of symptomatic breast
cancer. On behalf of the European Society of Surgical Oncology. Ann Chir Gynaecol 1998; 87: 101-109
23 Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with
more than three positive nodes. Ten-year results. JAMA 1995; 273: 542-547
24 Borner M, Bacchi M, Goldhirsch A et al. First isolated locoregional recurrence following mastectomy for breast cancer:
results of a phase III multicenter study comparing systemic treatment with
observation after excision and radiation. Swiss Group for Clinical Cancer
Research. J Clin Oncol 1994; 12: 2071-2077
25 Bornhak S, Heidemann E, Herschlein HJ et al. Symptom-oriented follow-up of early breast cancer is not inferior to
conventional control. Results of a prospective multicentre study. Onkologie 2007; 30: 443-449
26 Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a
meta-analysis. Cancer 1999; 85: 616-628
27 Bria E, Nistico C, Cuppone F et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled
analysis of 15,500 patients. Cancer 2006; 106: 2337-2344
28 Brito RA, Valero V, Buzdar AU et al. Long-term results of combined-modality therapy for locally advanced breast
cancer with ipsilateral supraclavicular metastases: The University of Texas M.D.
Anderson Cancer Center experience. J Clin Oncol 2001; 19: 628-633
29 Brown JE, Coleman RE. Metastatic bone disease: developing strategies to optimize management.
[DKG-R]. Am J Cancer 2003; 2: 269-281
30 Bruera E, Willey JS, Palmer JL et al. Treatment decisions for breast carcinoma: patient preferences and physician
perceptions. Cancer 2002; 94: 2076-2080
31 Buchholz TA. Radiation therapy for early-stage breast cancer after breast-conserving
surgery. N Engl J Med 2009; 360: 63-70
32 Buchholz TA, Lehman CD, Harris JR et al. Statement of the science concerning locoregional treatments after preoperative
chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 2008; 26: 791-797
33 Buchholz TA, Tucker SL, Masullo L et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and
mastectomy without radiation. J Clin Oncol 2002; 20: 17-23
34 Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of
breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-1211
35 Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001; 27: 137-142
36 Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with
HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730
37 Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on
adjuvant endocrine therapy for women with hormone receptor-positive breast
cancer. J Clin Oncol 2010; 28: 3784-3796
38 Butow P, Harrison JD, Choy ET et al. Health professional and consumer views on involving breast cancer patients in
the multidisciplinary discussion of their disease and treatment plan. Cancer 2007; 110: 1937-1944
39 Cady B, Stone MD, Wayne J. New therapeutic possibilities in primary invasive breast cancer. Ann Surg 1993; 218: 338-347
40 Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a
critical review of the literature. Int J Cancer 2004; 112: 357-364
41 Cardillo G, Facciolo F, Carbone L et al. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent
pleural effusions. Eur J Cardiothorac Surg 2002; 21: 302-305
42 Carlson RW, Moench SJ, Hammond ME et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006; 4 (Suppl. 03) S1-S22
43 Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer
cases. Cancer 1989; 63: 181-187
44 Chan DN, Lui LY, So WK. Effectiveness of exercise programmes on shoulder mobility and lymphoedema after
axillary lymph node dissection for breast cancer: systematic review. J Adv Nurs 2010; 66: 1902-1914
45 Chargari C, Kirov KM, Bollet MA et al. Cardiac toxicity in breast cancer patients: from a fractional point of view to a
global assessment. Cancer Treat Rev 2011; a 37: 321-330
46 Chargari C, Levy A, Vedrine L et al. Current trials of cytotoxic and targeted agents in breast cancer: the caveat of
radiotherapy. Ann Oncol 2011; b 22: 1243-1244
47 Cheema B, Gaul CA, Lane K et al. Progressive resistance training in breast cancer: a systematic review of
clinical trials. Breast Cancer Res Treat 2008; 109: 9-26
48 Cheung KL, Willsher PC, Pinder SE et al. Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat 1997; 45: 219-224
49 Christiaens M, Vlayen J, Gailly J. Scientific Support of the College of Oncology: a national clinical Practice
Guideline for Breast Cancer. KCE Report 63A. Brüssel: Belgian Health Care Knowledge Centre (KCE); 2007
50 Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential
versus concurrent combination chemotherapy as postoperative adjuvant treatment
of node-positive primary breast cancer: first report of Intergroup Trial
C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439
51 Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early
breast cancer on local recurrence and 15-year survival: an overview of the
randomised trials. Lancet 2005; 366: 2087-2106
52 Clavarezza M, Del Mastro L, Venturini M. Taxane-containing chemotherapy in the treatment of early breast cancer
patients. Ann Oncol 2006; 17 (Suppl. 07) vii22-vii26
53 Clohisy DR. Metastatic bone disease: future directions. Clin Orthop Relat Res 2003; 1 (415 Suppl.) 1-5
54 Carrick S, Parker S, Thornton CE et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009; (2) CD003372
55 Carrick S, Parker S, Wilcken N et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005; (2) CD003372
56 Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008; (2) CD006145
57 Edwards AG, Hailey S, Maxwell M. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 2004; (2) CD004253
58 Farquhar C, Marjoribanks J, Basser R et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation
versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 2005; (3) CD003142
59 Ferguson T, Wilcken N, Vagg R et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007; (4) CD004421
60 Gibson L, Lawrence D, Dawson C et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal
women. Cochrane Database Syst Rev 2009; (4) CD003370
61 Goodwin A, Parker S, Ghersi D et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2009; (4) CD000563
62 Hart MG, Grant R, Walker M et al. Surgical resection and whole brain radiation therapy versus whole brain
radiation therapy alone for single brain metastases. Cochrane Database of Systematic Review 2004; (4) CD003292
63 Hickey BE, Francis D, Lehman MH. Sequencing of chemotherapy and radiation therapy for early breast cancer. Cochrane Database Syst Rev 2006; (4) CD005212
64 Horneber MA, Bueschel G, Huber R et al. Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008; (2) CD003297
65 Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010; CD002748
66 Markes M, Brockow T, Resch KL. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 2006; (4) CD005001
67 McNeely ML, Campbell K, Ospina M et al. Exercise interventions for upper-limb dysfunction due to breast cancer
treatment. Cochrane Database Syst Rev 2010; (6) CD005211
68 Rauschecker H, Clarke M, Gatzemeier W et al. Systemic therapy for treating locoregional recurrence in women with breast
cancer. Cochrane Database Syst Rev 2001; (4) CD002195
69 Rauschecker HHF, Clarke MJ, Gatzemeier W et al. Systemic therapy for treating locoregional recurrence in women with breast
cancer. Cochrane Database Syst Rev 2008; (5) CD002195
70 Rojas MP, Telaro E, Russo A et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2000; (4) CD001768
71 Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, Palli D, del Roselli
TM, Liberati A. Follow-up strategies for women treated for early breast
cancer. Cochrane Database Syst Rev 2005; (1) CD001768
72 Colleoni M, Rotmensz N, Maisonneuve P et al. Prognostic role of the extent of peritumoral vascular invasion in operable
breast cancer. Ann Oncol 2007; 18: 1632-1640
73 Conte PF, Latreille J, Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with
intravenous pamidronate: results from a multinational randomized controlled
trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996; 14: 2552-2559
74 Crump M. The role of trastuzumab (Herceptin) in the treatment of women with HER2/neu –
overexpressing metastatic breast cancer. Practice Guideline Report no. 1 – 15
(Version 2.2004). Toronto (ON): Cancer Care Ontario; 2005
75 Crump M, Goss PE, Prince M et al. Outcome of extensive evaluation before adjuvant therapy in women with breast
cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996; 14: 66-69
76 Cutuli B, Cohen-Solal-le Nir C, de Lafontan B et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French
Cancer Centersʼ experience. Int J Radiat Oncol Biol Phys 2002; 53: 868-879
77 Cuzick J, Sestak I, Pinder SE et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal
carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011; 12: 21-29
78 Dalberg K, Mattsson A, Sandelin K et al. Outcome of treatment for ipsilateral breast tumor recurrence in early-stage
breast cancer. Breast Cancer Res Treat 1998; 49: 69-78
79 Darby S. on Behalf of the Early Breast Cancer Trialistsʼ Collaborative
Group, University of Oxford, GB. Overview of the randomised trials of radiotherapy in early breast cancer.
SABCS2009; Minisymposium 3, 1. [MS3–1], Slides of the oral presentation at the
32nd Annual SABCS2009:. http://www.sabcs.org/
80 de Azambuja E, Cardoso F, de Castro Jr. G et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12,155 patients. Br J Cancer 2007; 96: 1504-1513
81 de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009; 361: 653-663
82 de Boer M, van Dijck JA, Bult P et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells,
and micrometastases. J Natl Cancer Inst 2010; 102: 410-425
83 Del Turco MR, Ponti A, Bick U et al. Quality indicators in breast cancer care. Eur J Cancer 2010; 46: 2344-2356
84 Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after
previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys 2002; 53: 687-691
85 Devoogdt N, Van Kampen M, Geraerts I et al. Different physical treatment modalities for lymphoedema developing after
axillary lymph node dissection for breast cancer: a review. Eur J Obstet Gynecol Reprod Biol 2010; 149: 3-9
86 Domchek SM, Friebel TM, Neuhausen SL et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation
carriers: a prospective cohort study. Lancet Oncol 2006; 7: 223-229
87 Dowsett M, Nielsen TO, Aʼhern R et al. Assessment of ki67 in breast cancer: recommendations from the international ki67
in breast cancer working group. J Natl Cancer Inst 2011; 103: 1656-1664
88 DRV Bund. Deutsche Rentenversicherung Bund. Reha-Therapiestandards Brustkrebs. Leitlinie
für die medizinische Rehabilitation der Rentenversicherung. http://deutsche-rentenversicherung.de
89 Dunne C, Burke JP, Morrow M et al. Effect of margin status on local recurrence after breast conservation and
radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009; 27: 1615-1620
90 EBCTCG. Effects of radiotherapy and surgery in early breast cancer. An overview of the
randomized trials. Early Breast Cancer Trialistsʼ Collaborative Group. N Engl J Med 1995; 333: 1444-1455
91 EBCTCG. Polychemotherapy for early breast cancer: an overview of the randomised trials.
Early Breast Cancer Trialistsʼ Collaborative Group. Lancet 1998; 352: 930-942
92 EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised trials.Early
Breast Cancer Trialistsʼ Collaborative Group. Lancet 2005; 365: 1687-1717
93 EBCTCG. Comparisons between different polychemotherapy regimes for early breast cancer:
meta-analysis of long-term outcome among 100000 women in 123 randomised
trials. Lancet 2011; Published online December 6, 2011
94 Darby S, McGale P, Correa C et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and
15-year breast cancer death: meta-analysis of individual patient data for 10,801
women in 17 randomised trials. Lancet 2011; 378: 1707-1716
95 Correa C, McGale P, Taylor C et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of
the breast. J Natl Cancer Inst Monogr 2010; 2010: 162-177
96 Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy
of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784
97 Early Breast Cancer Trialistsʼ Collaborative
Group. Multi-agent chemotherapy for early breast cancer. [DKG-R]. Cochrane Database Syst Rev 2003; (3) CD00487
98 EBMG. Evidence-based medicine guidelines 2006. Article ID: evd02580 (025.023). http://www.awmf.org
99 EGAPP Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression
profiling improve outcomes in patients with breast cancer?. Genet Med 2009; 11: 66-73
100 Eiermann W, Pienkowski T, Crown J et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus
sequential docetaxel as adjuvant treatment in patients with human epidermal
growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005
trial. J Clin Oncol 2011; 29: 3877-3884
101 Elkin EB, Kim SH, Casper ES et al. Desire for information and involvement in treatment decisions: elderly cancer
patientsʼ preferences and their physiciansʼ perceptions. J Clin Oncol 2007; 25: 5275-5280
102 Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. [AGO]. Cancer 2000; 749-797
103 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: experience from a large study with long-term
follow-up. Histopathology 1991; 19: 403-410
104 Emdin SO, Granstrand B, Ringberg A et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the
breast. Results of a randomised trial in a population offered mammography
screening. Acta Oncol 2006; 45: 536-543
105 Estevez LG, Munoz M, Alvarez I et al. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review
of randomized phase III trials. Cancer Treat Rev 2007; 33: 474-483
106 Evans DG, Baildam AD, Anderson E et al. Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet 2009; 46: 254-258
107 Feher O, Vadvorka P, Jassem J et al. Randomized phase III study of epirubicin (E) versus gemcitabine (G) chemotherapy
in elderly females with metastatic breast cancer (MBC). Jk 3 2002; EBCC,
Barcelona. [AGO].
108 Fernando SA, Edge SB. Evidence and controversies in the use of post-mastectomy radiation. J Natl Compr Canc Netw 2007; 5: 331-338
109 Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of
the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel
Project. World J Surg 1994; 18: 63-69
110 Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a
doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer:
findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; a 15: 1858-1869
111 Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with
operable breast cancer: findings from National Surgical Adjuvant Breast and
Bowel Project B-18. J Clin Oncol 1997; b 15: 2483-2493
112 Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction
therapy compared with 6 months of cyclophosphamide, methotrexate, and
fluorouracil in positive-node breast cancer patients with
tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant
Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496
113 Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive
breast cancer. J Natl Cancer Inst 1997; c 89: 1673-1682
114 Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant
Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000
115 Fisher B, Land S, Mamounas E et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an
update of the national surgical adjuvant breast and bowel project
experience. Semin Oncol 2001; 28: 400-418
116 Fleissig A, Fallowfield LJ, Langridge CI et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC
randomised trial comparing sentinel node biopsy with standard axillary treatment
in the management of patients with early breast cancer. Breast Cancer Res Treat 2006; 95: 279-293
117 Floyd SR, Taghian AG. Post-mastectomy radiation in large node-negative breast tumors: does size really
matter?. Radiother Oncol 2009; 91: 33-37
118 Ford S, Schofield T, Hope T. Observing decision-making in the general practice consultation: who makes which
decisions?. Health Expect 2006; 9: 130-137
119 Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic
review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460
120 Fourney DR, Gokaslan ZL. Thoracolumbar spine: surgical treatment of metastatic disease. [DKG-R]. Current Opinion in Orthopedics 2003; 14: 144-152
121 Francis P, Crown J, Di Leo A et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel:
Breast International Group 02–98 randomized trial. J Natl Cancer Inst 2008; 100: 121-133
122 Francis WP, Abghari P, Du W et al. Improving surgical outcomes: standardizing the reporting of incidence and
severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph
node dissection. Am J Surg 2006; 192: 636-639
123 French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for
node-positive breast cancer patients with poor prognostic factors: 5-year
follow-up results of French Adjuvant Study Group 05 Randomized Trial.
[CANADA]. J Clin Oncol 2001; 19: 602-611
124 Fumoleau P, Kerbrat P, Romestaing P et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant
chemotherapy in premenopausal, node-positive breast cancer patients: 10-year
follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003; 21: 298-305
125 Garg AK, Oh JL, Oswald MJ et al. Effect of postmastectomy radiotherapy in patients < 35 years old with stage
II–III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and
mastectomy. Int J Radiat Oncol Biol Phys 2007; 69: 1478-1483
126 Gasparini G, Weidner N, Bevilacqua P et al. Tumor microvessel density, p 53 expression, tumor size, and peritumoral
lymphatic vessel invasion are relevant prognostic markers in node-negative
breast carcinoma. J Clin Oncol 1994; 12: 454-466
127 Gebski V, Lagleva M, Keech A et al. Survival effects of postmastectomy adjuvant radiation therapy using biologically
equivalent doses: a clinical perspective. J Natl Cancer Inst 2006; 98: 26-38
128 Geller BM, Kerlikowske K, Carney PA et al. Mammography surveillance following breast cancer. Breast Cancer Res Treat 2003; 81: 107-115
129 GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in
breast cancer patients. A multicenter randomized controlled trial. The GIVIO
Investigators. JAMA 1994; 271: 1587-1592
130 Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329
131 Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes – dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747
132 Golshan M, Martin WJ, Dowlatshahi K. Sentinel lymph node biopsy lowers the rate of lymphedema when compared with
standard axillary lymph node dissection. Am Surg 2003; 69: 209-211
133 Gruber R, Bernt R, Helbich TH. [Cost-effectiveness of percutaneous core needle breast biopsy (CNBB) versus open
surgical biopsy (OSB) of nonpalpable breast lesions: metaanalysis and cost
evaluation for German-speaking countries]. Rofo 2008; 180: 134-142
134 Grunfeld E, Dhesy-Thind S, Levine M. Clinical practice guidelines for the care and treatment of breast cancer:
follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ 2005; 172: 1319-1320
135 Grunfeld E, Noorani H, McGahan L et al. Surveillance mammography after treatment of primary breast cancer: a systematic
review. Breast 2002; 11: 228-235
136 Gulliford T, Opomu M, Wilson E et al. Popularity of less frequent follow up for breast cancer in randomised study:
initial findings from the hotline study. BMJ 1997; 314: 174-177
137 Haffty BG, Reiss M, Beinfield M et al. Ipsilateral breast tumor recurrence as a predictor of distant disease:
implications for systemic therapy at the time of local relapse. J Clin Oncol 1996; 14: 52-57
138 Harbeck N, Schmitt M, Meisner C et al. Final 10-year analysis of prospective multicenter Chemo N0 trial for validation
of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in
node-negative breast cancer. J Clin Oncol 2009; 27 (Suppl. 15) Abstr. 511
139 Halyard MY, Pisansky TM, Dueck AC et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability
and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009; 27: 2638-2644
140 Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline
recommendations for immunohistochemical testing of estrogen and progesterone
receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795
141 Hamner JB, Fleming MD. Lymphedema therapy reduces the volume of edema and pain in patients with breast
cancer. Ann Surg Oncol 2007; 14: 1904-1908
142 Harnett A. Fewer fractions of adjuvant external beam radiotherapy for early breast cancer
are safe and effective and can now be the standard of care. Why the UKʼs NICE
accepts fewer fractions as the standard of care for adjuvant radiotherapy in
early breast cancer. Breast 2010; 19: 159-162
143 Harnett A, Smallwood J, Titshall V et al. Diagnosis and treatment of early breast cancer, including locally advanced
disease – summary of NICE guidance. BMJ 2009; 338: b438
144 Harris EE. Cardiac mortality and morbidity after breast cancer treatment. Cancer Control 2008; 15: 120-129
145 Harris EE, Christensen VJ, Hwang WT et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in
early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 2005; 23: 11-16
146 Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use
of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312
147 Harris SR, Hugi MR, Olivotto IA et al. Clinical practice guidelines for the care and treatment of breast cancer: 11.
Lymphedema. CMAJ 2001; 164: 191-199
148 Hauner D, Janni W, Rack B et al. The effect of overweight and nutrition on prognosis in breast cancer. Dtsch Arztebl Int 2011; 108: 795-801
149 Hayes DF. Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med 2007; 356: 2505-2513
150 Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 1995; 22 (2 Suppl. 5) 5-19
151 Hayes S, Cornish B, Newman B. Comparison of methods to diagnose lymphoedema among breast cancer survivors:
6-month follow-up. Breast Cancer Res Treat 2005; 89: 221-226
152 Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential Paclitaxel but not from escalating
Doxorubicin dose in an adjuvant chemotherapy regimen for patients with
node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983
153 Hoeller U, Borgmann K, Feyer P et al. [On the interaction of adjuvant radiotherapy and tamoxifen treatment for breast
cancer]. Strahlenther Onkol 2007; 183: 535-544
154 Holmberg L, Garmo H, Granstrand B et al. Absolute risk reductions for local recurrence after postoperative radiotherapy
after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 2008; 26: 1247-1252
155 Honrado E, Osorio A, Palacios J et al. Pathology and gene expression of hereditary breast tumors associated with BRCA1,
BRCA2 and CHEK2 gene mutations. Oncogene 2006; 25: 5837-5845
156 Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Semin Oncol 1996; 23 (5 Suppl. 11) 1-5
157 Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with
pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-2044
158 Hoskin PJ, Yarnold JR, Roos DR et al. Second workshop on palliative radiotherapy and symptom control: radiotherapy for
bone metastases. [DKG-N]. Clin Oncol (R Coll Radiol). Clin Oncol 2001; 13: 88-90
159 Houghton J, George WD, Cuzick J et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in
situ of the breast in the UK, Australia, and New Zealand: randomised controlled
trial. Lancet 2003; 362: 95-102
160 Houssami N, Ciatto S, Macaskill P et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer
staging: systematic review and meta-analysis in detection of multifocal and
multicentric cancer. J Clin Oncol 2008; 26: 3248-3258
161 Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should
MRI be performed on all women with newly diagnosed, early stage breast
cancer?. CA Cancer J Clin 2009; 59: 290-302
162 Houssami N, Macaskill P, Marinovich ML et al. Meta-analysis of the impact of surgical margins on local recurrence in women
with early-stage invasive breast cancer treated with breast-conserving
therapy. Eur J Cancer 2010; 46: 3219-3232
163 Huang EH, Strom EA, Perkins GH et al. Comparison of risk of local-regional recurrence after mastectomy or breast
conservation therapy for patients treated with neoadjuvant chemotherapy and
radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 2006; 66: 352-357
164 Hurria A, Hudis C. Follow-up care of breast cancer survivors. Crit Rev Oncol Hematol 2003; 48: 89-99
165 ICSI. Health care guideline: breast cancer treatment. http://www.guideline.gov
166 Jagsi R, Pierce L. Postmastectomy radiation therapy for patients with locally advanced breast
cancer. Semin Radiat Oncol 2009; 19: 236-243
167 Janicke F, Prechtl A, Thomssen C et al. German N0 Study Group. Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer
patients identified by urokinase-type plasminogen activator and plasminogen
activator inhibitor type I. J Natl Cancer Inst 2001; 93: 913-920
168 Johnson RC, Banerjee D, Webster DJ. Mastectomy follow-up by biennial mammograms: is it worthwhile?. Breast 2000; 9: 93-95
169 Jones HA, Antonini N, Hart AA et al. Impact of pathological characteristics on local relapse after breast-conserving
therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009; 27: 4939-4947
170 Jones EL, Oleson JR, Prosnitz LR et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005; 23: 3079-3085
171 Jubelirer SJ. Surveillance testing in patients with early stage breast cancer: a review. W V Med J 1998; 94: 14-17
172 Karasawa K, Katsui K, Seki K et al. Radiotherapy with concurrent docetaxel for advanced and recurrent breast
cancer. Breast Cancer 2003; 10: 268-274
173 Kato T, Kameoka S, Kimura T et al. The combination of angiogenesis and blood vessel invasion as a prognostic
indicator in primary breast cancer. Br J Cancer 2003; 88: 1900-1908
174 Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant
(primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24: 1940-1949
175 Kaufmann M, Morrow M, von Minckwitz G et al. Locoregional treatment of primary breast cancer: consensus recommendations from
an International Expert Panel. Cancer 2010; 116: 1184-1191
176 Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the use of primary (preoperative) systemic
treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21: 2600-2608
177 Kelly CM, Wilkins RM, Eckardt JJ et al. Treatment of metastatic disease of the tibia. Clin Orthop Relat Res 2003; 1 (415 Suppl.) S219-S229
178 Khatcheressian JL, Wolff AC, Smith TJ et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up
and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24: 5091-5097
179 Kirova YM, Caussa L, Granger B et al. [Monocentric evaluation of the skin and cardiac toxicities of the concomitant
administration of trastuzumab and radiotherapy]. Cancer Radiother 2009; 13: 276-280
180 Klemperer D, Lang B, Koch K et al. Gute Praxis Gesundheitsinformation. Z Evid Fortbild Qual Gesundh wesen (ZEFQ) 2010; 104: 66-68
181 Klijn JG, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist
versus LHRH agonist alone in premenopausal advanced breast cancer: a
meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-353
182 Koizumi M, Yoshimoto M, Kasumi F et al. Comparison between solitary and multiple skeletal metastatic lesions of breast
cancer patients. Ann Oncol 2003; 14: 1234-1240
183 Kollias J, Evans AJ, Wilson AR et al. Value of contralateral surveillance mammography for primary breast cancer
follow-up. World J Surg 2000; 24: 983-987
184 Kondziolka D, Patel A, Lunsford LD et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy
alone for patients with multiple brain metastases. [DKG-N]. Int J Radiat Oncol Biol Phys 1999; 45: 427-434
185 Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node
dissection in clinically node-negative patients with breast cancer: overall
survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11: 927-933
186 Kuehn T, Bembenek A, Decker T et al. A concept for the clinical implementation of sentinel lymph node biopsy in
patients with breast carcinoma with special regard to quality assurance. Cancer 2005; 103: 451-461
187 Kunkler I. Adjuvant chest wall radiotherapy for breast cancer: black, white and shades of
grey. Eur J Surg Oncol 2010; 36: 331-334
188 Kurtz JM, Amalric R, Brandone H et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency,
time course, and prognosis. Cancer 1989; 63: 1912-1917
189 Kurtz JM, Jacquemier J, Amalric R et al. Is breast conservation after local recurrence feasible?. Eur J Cancer 1991; 27: 240-244
190 Kyndi M, Sorensen FB, Knudsen H et al. Impact of BCL2 and p 53 on postmastectomy radiotherapy response in high-risk
breast cancer. A subgroup analysis of DBCG82 b&c. Acta Oncol 2008; a 47: 608-617
191 Kyndi M, Sorensen FB, Knudsen H et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy
radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative
Group. J Clin Oncol 2008; b 26: 1419-1426
192 Lakhani SR, Jacquemier J, Sloane JP et al. Multifactorial analysis of differences between sporadic breast cancers and
cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90: 1138-1145
193 Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen
receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175-5180
194 Lanitis S, Tekkis PP, Sgourakis G et al. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for
breast cancer: a meta-analysis of observational studies. Ann Surg 2010; 251: 632-639
195 Lemieux J, Goodwin PJ, Bordeleau LJ et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an
updated systematic review (2001–2009). J Natl Cancer Inst 2011; 103: 178-231
196 Livi L, Borghesi S, Saieva C et al. Benefit of radiation boost after whole-breast radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 1029-1034
197 Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and
its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-128
198 Loprinzi CL. Follow-up care after breast cancer treatment. Mayo Clin Womens Healthsource 2004; 8 (Suppl. 12)
199 Lupe K, Truong PT, Alexander C et al. Ten-year locoregional recurrence risks in women with nodal micrometastatic
breast cancer staged with axillary dissection. Int J Radiat Oncol Biol Phys 2011; 81: e681-e688
200 Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical Oncology guideline recommendations for sentinel
lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703-7720
201 Madjar H. Role of breast ultrasound for the detection and differentiation of breast
lesions. Breast Care (Basel) 2010; 5: 109-114
202 Madjar H, Mundinger A, Degenhardt F et al. Qualitätskontrolle in der Mamma-Sonographie. Ultraschall in Med 2003; 24: 190-194
203 Madjar H, Ohlinger R, Mundinger A et al. BI-RADS-analogue DEGUM criteria for findings in breast ultrasound – consensus of
the DEGUM Committee on Breast Ultrasound. Ultraschall Med 2006; 27: 374-379
204 Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for
node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696
205 Mansel RE, Fallowfield L, Kissin M et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary
treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98: 599-609
206 Marchionni L, Wilson RF, Wolff AC et al. Systematic review: gene expression profiling assays in early-stage breast
cancer. Ann Intern Med 2008; 148: 358-369
207 McCammon R, Finlayson C, Schwer A et al. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast:
a Surveillance, Epidemiology, and End Results database analysis. Cancer 2008; 113: 683-689
208 McGuire SE, Gonzalez-Angulo AM, Huang EH et al. Postmastectomy radiation improves the outcome of patients with locally advanced
breast cancer who achieve a pathologic complete response to neoadjuvant
chemotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1004-1009
209 Moebus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and
cyclophosphamide compared with conventionally scheduled chemotherapy in
high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28: 2874-2880
210 Moseley AL, Carati CJ, Piller NB. A systematic review of common conservative therapies for arm lymphoedema
secondary to breast cancer treatment. Ann Oncol 2007; 18: 639-646
211 Mouridsen H, Sun Y, Gershanovich M et al. First-line therapy with letrozole (Femara) for advanced breast cancer prolongs
time to worsening of Karnofsky Performance Status compared with tamoxifen. Breast Canc Res Treat 2001; a 69:
212 Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for
postmenopausal women with advanced breast cancer: results of a phase III study
of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; b 19: 2596-2606
213 NBOCC, National Breast and Ovarian Cancer
Center. Recommendations for use of Chemotherapy for the treatment of advanced breast
cancer. Surry Hills: NBOCC; 2010. a
214 NBOCC, National Breast and Ovarian Cancer
Centre. Recommendations for follow-up of women with early breast cancer. Surry Hills: NBOCC; 2010. b
215 NCCN. Practice guidelines in oncology – Version 2. Fort Washington, PA (USA): NCCN; 2006
216 NCCN. Clinical practice guidelines in oncology: breast cancer – Version V.1. Fort Washington, PA (USA): NCCN; 2007
217 NCCN, National Comprehensive Cancer Network. Breast cancer. V. 2.2011. Fort Washington, PA (USA): NCCN; 2011
218 NCRI. UK clinical guidelines for the use of adjuvant trastuzumab (Herceptin®) with or
following chemotherapy in HER2-positive early breast cancer. London (UK): NCRI; 2005
219 NHMRC. Clinical practice guidelines for the management of early breast cancer. Canberra (Australien): NHMRC; 2001
220 National Institute for Clinical Excellence
(NICE). Advanced breast cancer: diagnosis and treatment. London (UK): NICE; 2009. a
221 National Institute for Clinical Excellence
(NICE). Early and locally advanced breast cancer: diagnosis and treatment. London (UK): NICE; 2009. b
222 Nielsen HM, Overgaard M, Grau C et al. Loco-regional recurrence after mastectomy in high-risk breast cancer – risk and
prognosis. An analysis of patients from the DBCG 82 b&c randomization
trials. Radiother Oncol 2006; a 79: 147-155
223 Nielsen HM, Overgaard M, Grau C et al. Study of failure pattern among high-risk breast cancer patients with or without
postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term
results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c
randomized studies. J Clin Oncol 2006; b 24: 2268-2275
224 NIH, National Institutes of Health Consensus Development
Panel. National Institutes of Health Consensus Development Conference statement:
adjuvant therapy for breast cancer November 1 – 3, 2000. [CANADA]. Bethesda
2001. Bethesda (MD): NIH; 2001. http://odp.od.nih.gov/consensus/cons/114/114_statement.htm last access: 2001
225 Nothacker M, Duda V, Hahn M et al. Early detection of breast cancer: benefits and risks of supplemental breast
ultrasound in asymptomatic women with mammographically dense breast tissue. A
systematic review. BMC Cancer 2009; 9: 335
226 Nothacker M, Lelgemann M, Giersiepen K et al. Evidenzbericht 2007 zur S3-Leitlinie Brustkrebsfrüherkennung in Deutschland. Berlin: Ärztliches Zentrum für Qualität in der Medizin; 2007
227 NZGG, New Zealand Guidelines Group. Management of early breast cancer. Wellington: NZGG; 2009
228 OʼHiggins N, Linos DA, Blichert-Toft M et al. European guidelines for quality assurance in the surgical management of
mammographically detected lesions. Eur J Surg Oncol 1998; 24: 96-98
229 OʼRourke N, McCloskey E, Houghton F et al. Double-blind, placebo-controlled, dose-response trial of oral clodronate in
patients with bone metastases. J Clin Oncol 1995; 13: 929-934
230 Omlin A, Amichetti M, Azria D et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre,
retrospective study of the Rare Cancer Network. Lancet Oncol 2006; 7: 652-656
231 Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998; 51: 227-238
232 Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or
more positive nodes, as recommended in international consensus reports? A
subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007; 82: 247-253
233 Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat 1998; 51: 195-208
234 Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical
ductal hyperplasia. Hum Pathol 1992; 23: 1095-1097
235 Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative
breast cancer. N Engl J Med 2004; 351: 2817-2826
236 Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734
237 Palli D, Russo A, Saieva C et al. Intensive vs. clinical follow-up after treatment of primary breast cancer:
10-year update of a randomized trial. National Research Council Project on
Breast Cancer Follow-up. JAMA 1999; 281: 1586
238 Park CC, Mitsumori M, Nixon A et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for
invasive breast cancer: influence of margin status and systemic therapy on local
recurrence. J Clin Oncol 2000; 18: 1668-1675
239 Pestalozzi BC, Luporsi-Gely E, Jost LM et al. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and
follow-up of primary breast cancer. Ann Oncol 2005; 16 (Suppl. 01) i7-i9
240 Peto R. Highlights from the 2005/6 EBCTCG worldwide overview of every women in all the
trials in early breast cancer. 29th Annual San Antonio Breast Cancer Symposium
2006; Abstract book # 40.
241 Petrelli F, Barni S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in
breast cancer: the sooner the better. Med Oncol 2012; 29: 503-510
242 Pierce LJ, Hutchins LF, Green SR et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in
early-stage breast cancer. J Clin Oncol 2005; 23: 24-29
243 Politi MC, Han PK, Col NF. Communicating the uncertainty of harms and benefits of medical
interventions. Med Decis Making 2007; 27: 681-695
244 Poortmans P. Evidence based radiation oncology: breast cancer. Radiother Oncol 2007; 84: 84-101
245 Poortmans PM, Collette L, Bartelink H et al. The addition of a boost dose on the primary tumour bed after lumpectomy in
breast conserving treatment for breast cancer. A summary of the results of
EORTC22881–10882 “boost versus no boost” trial. Cancer Radiother 2008; 12: 565-570
246 Poortmans PM, Collette L, Horiot JC et al. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage
breast cancer after a microscopically incomplete lumpectomy: 10-year results of
the randomised EORTC boost trial. Radiother Oncol 2009; 90: 80-85
247 Potter S, Brigic A, Whiting PF et al. Reporting clinical outcomes of breast reconstruction: a systematic review. J Natl Cancer Inst 2011; 103: 31-46
248 Recht A. Integration of systemic therapy and radiation therapy for patients with
early-stage breast cancer treated with conservative surgery. Clin Breast Cancer 2003; 4: 104-113
249 Recht A. Radiotherapy, antihormonal therapy, and personalised medicine. Lancet Oncol 2010; 11: 215-216
250 Renton SC, Gazet JC, Ford HT et al. The importance of the resection margin in conservative surgery for breast
cancer. Eur J Surg Oncol 1996; 22: 17-22
251 Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of
chemotherapy with or without bevacizumab for first-line treatment of human
epidermal growth factor receptor 2-negative, locally recurrent or metastatic
breast cancer. J Clin Oncol 2011; 29: 1252-1260
252 Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in
postmenopausal women: a prospective combined analysis of two multicenter
trials. Cancer 2003; 98: 229-238
253 Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for
node-positive breast cancer patients: the FNCLCC PACS01 Trial. J Clin Oncol 2006; 24: 5664-5671
254 Romestaing P, Belot A, Hennequin C. Ten-year results of a randomized trial of internal mammary chain irradiation
after mastectomy. Int J Radiat Oncol Biol Phys 2009; 75 (Suppl. 03) p S1 [Abstract 1]
255 Romestaing P, Lehingue Y, Carrie C et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer:
results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997; 15: 963-968
256 Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast
cancer. N Engl J Med 2005; 353: 1673-1684
257 Roos DE, OʼBrien PC, Smith JG et al. A role for radiotherapy in neuropathic bone pain: preliminary response rates
from a prospective trial (Trans-tasman radiation oncology group, TROG
96.05). Int J Radiat Oncol Biol Phys 2000; 46: 975-981
258 Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in
patients with breast cancer or osteolytic lesions of multiple myeloma: a phase
III, double-blind, comparative trial. Cancer J 2001; 7: 377-387
259 Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991; 9: 1650-1661
260 Rosen PP, Groshen S, Kinne DW et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of
767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993; 11: 2090-2100
261 Rosselli Del T, Palli D, Cariddi A et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A
randomized trial. National Research Council Project on Breast Cancer
follow-up. JAMA 1994; 271: 1593-1597
262 Rouesse J, de la Lande B, Bertheault-Cvitkovic F et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy
versus standard adjuvant chemotherapy followed by radiotherapy in operable
node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys 2006; 64: 1072-1080
263 Rowell NP. Radiotherapy to the chest wall following mastectomy for node-negative breast
cancer: a systematic review. Radiother Oncol 2009; 91: 23-32
264 Rowell NP. Are mastectomy resection margins of clinical relevance? A systematic review. Breast 2010; 19: 14-22
265 Russell NS, Kunkler IH, van Tienhoven G et al. Postmastectomy radiotherapy: will the selective use of postmastectomy
radiotherapy study end the debate?. J Clin Oncol 2009; 27: 996-997
266 S3 Leitlinie Magenkarzinom. Diagnostik und Therapie der Adenokarzinome des
Magens und ösophagogastralen Übergangs. AWMF; 2011
267 Sanjuan A, Vidal-Sicart S, Zanon G et al. Clinical axillary recurrence after sentinel node biopsy in breast cancer: a
follow-up study of 220 patients. Eur J Nucl Med Mol Imaging 2005; 32: 932-936
268 Sautter-Bihl ML, Budach W, Dunst J et al. DEGRO practical guidelines for radiotherapy of breast cancer I:
breast-conserving therapy. Strahlenther Onkol 2007; 183: 661-666
269 Schmoor C, Sauerbrei W, Bastert G et al. Role of isolated locoregional recurrence of breast cancer: results of four
prospective studies. J Clin Oncol 2000; 18: 1696-1708
270 Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with
analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-2595
271 Selby P, Gillis C, Haward R. Benefits from specialised cancer care. Lancet 1996; 348: 313-318
272 Semrau S, Gerber B, Reimer T et al. Concurrent radiotherapy and taxane chemotherapy in patients with locoregional
recurrence of breast cancer. A retrospective analysis. Strahlenther Onkol 2006; 182: 596-603
273 Shaffer R, Tyldesley S, Rolles M et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including
internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 2009; 90: 122-126
274 Shafiq J, Delaney G, Barton MB. An evidence-based estimation of local control and survival benefit of
radiotherapy for breast cancer. Radiother Oncol 2007; 84: 11-17
275 Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer
patients: results of two meta-analyses. Br J Cancer 1999; 80: 1770-1780
276 Shelley W, McCready D, Holloway C et al. and the Breast Cancer Disease Site Group. Management of ductal carcinoma in situ of the breast: a clinical practice
guideline. Evidence-based Series #1–10 Version 2.2006: Section 1. Hamilton, ON: Cancer Care Ontario; 2006
277 Shenkier T, Weir L, Levine M et al. Clinical practice guidelines for the care and treatment of breast cancer: 15.
Treatment for women with stage III or locally advanced breast cancer. CMAJ 2004; 170: 983-994
278 Sherar M, Liu FF, Pintilie M et al. Relationship between thermal dose and outcome in thermoradiotherapy treatments
for superficial recurrences of breast cancer: data from a phase III trial. Int J Radiat Oncol Biol Phys 1997; 39: 371-380
279 SIGN. SIGN 84: Management of breast cancer in women. Edinburgh (Scotland): SIGN; 2005
280 Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. [CANADA]. N Engl J Med 2001; 344: 783-792
281 Sledge Jr. GW, Hu P, Falkson G et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for
metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology
Group study. J Clin Oncol 2000; 18: 262-266
282 Smith BD, Bentzen SM, Correa CR et al. Fractionation for whole breast irradiation: an American Society for Radiation
Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 81: 59-68
283 Smith BD, Haffty BG, Buchholz TA et al. Effectiveness of radiation therapy in older women with ductal carcinoma in
situ. J Natl Cancer Inst 2006; 98: 1302-1310
284 Stadtmauer EA, OʼNeill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus
autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342: 1069-1076
285 Steenland E, Leer JW, van Houwelingen H et al. The effect of a single fraction compared to multiple fractions on painful bone
metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999; 52: 101-109
286 Stockler M, Wilcken N, Ghersi D et al. The management of advanced breast cancer: systemic reviews of randomised
controlled trials regarding the use of cytotoxic chemotherapy and endocrine
therapy. Woolloomooloo, Canberra (Australien): NHMRC; 1997
287 Stockler M, Wilcken NR, Ghersi D et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast
cancer. Cancer Treat Rev 2000; 26: 151-168
288 Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in
patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139
289 Taylor CW, Green S, Dalton WS et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy
in premenopausal patients with receptor-positive metastatic breast cancer: an
intergroup study. J Clin Oncol 1998; 16: 994-999
290 The Association of Breast Surgery at BASO
RCoSoE. Guidelines for the management of symptomatic breast disease. Eur J Surg Oncol 2005; 31 (Suppl. 01) 1-21
291 Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and
lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia
Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-854
292 Thuerlimann B, Price KN, Castiglione M et al. Randomized controlled trial of ovarian function suppression plus tamoxifen
versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary
for premenopausal women with node-positive, endocrine-responsive breast cancer?
First results of International Breast Cancer Study Group Trial 11–93.
[DKG-R]. Breast 2001; 10 (Suppl. 03) 130-138
293 Tjan-Heijnen VC, de Boer M. Minimal lymph node involvement and outcome of breast cancer. The results of the
Dutch MIRROR study. Discov Med 2009; 8: 137-139
294 Torrenga H, Fabry H, van der Sijp JR et al. Omitting axillary lymph node dissection in sentinel node negative breast cancer
patients is safe: a long term follow-up analysis. J Surg Oncol 2004; 88: 4-7
295 Truong PT, Olivotto IA, Kader HA et al. Selecting breast cancer patients with T1–T2 tumors and one to three positive
axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant
radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 1337-1347
296 Truong PT, Olivotto IA, Whelan TJ et al. Clinical practice guidelines for the care and treatment of breast cancer: 16.
Locoregional post-mastectomy radiotherapy. CMAJ 2004; 170: 1263-1273
297 Truong PT, Vinh-Hung V, Cserni G et al. The number of positive nodes and the ratio of positive to excised nodes are
significant predictors of survival in women with micrometastatic node-positive
breast cancer. Eur J Cancer 2008; 44: 1670-1677
298 Tsoutsou PG, Belkacemi Y, Gligorov J et al. Optimal sequence of implied modalities in the adjuvant setting of breast cancer
treatment: an update on issues to consider. Oncologist 2010; 15: 1169-1178
299 Turnbull L, Brown S, Harvey I et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised
controlled trial. Lancet 2010; 375: 563-571
300 UICC. TNM classification of malignant tumours. In: Sobin L, Gospodarowicz M, Wittekind C, eds. 7th ed. New York: Wiley-Liss; 2010
301 Velikova G, Booth L, Smith AB et al. Measuring quality of life in routine oncology practice improves communication
and patient well-being: a randomized controlled trial. J Clin Oncol 2004; 22: 714-724
302 Velikova G, Wright EP, Smith AB et al. Automated collection of quality-of-life data: a comparison of paper and computer
touch-screen questionnaires. J Clin Oncol 1999; 17: 998-1007
303 Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery
with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-1232
304 Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection
in breast cancer. N Engl J Med 2003; 349: 546-553
305 Vogel C, OʼRourke M, Winer E et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60
years of age or older. Ann Oncol 1999; 10: 397-402
306 Vogl TJ, Muller PK, Mack MG et al. Liver metastases: interventional therapeutic techniques and results, state of
the art. Eur Radiol 1999; 9: 675-684
307 von Minckwitz G, Kaufmann M, Möhrle D et al. Hormonelle Folgetherapien nach Goserelin (Zoladex®) beim metastasierten
Mammakarzinom prämenopausaler Patientinnen. [AGO]. Arch Gynecol Obst 1991; 250: 258-260
308 von Minckwitz G, Untch M, Nuesch E et al. Impact of treatment characteristics on response of different breast cancer
phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-156
309 Voogd AC, Nielsen M, Peterse JL et al. Differences in risk factors for local and distant recurrence after
breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled
results of two large European randomized trials. J Clin Oncol 2001; 19: 1688-1697
310 Voordeckers M, Vinh-Hung V, Lamote J et al. Survival benefit with radiation therapy in node-positive breast carcinoma
patients. Strahlenther Onkol 2009; 185: 656-662
311 Voskuil DW, van Nes JG, Junggeburt JM et al. Maintenance of physical activity and body weight in relation to subsequent
quality of life in postmenopausal breast cancer patients. Ann Oncol 2010; 21: 2094-2101
312 Wald NJ, Murphy P, Major P et al. UKCCCR multicentre randomised controlled trial of one and two view mammography
in breast cancer screening. BMJ 1995; 311: 1189-1193
313 Walker MP, Yaszemski MJ, Kim CW et al. Metastatic disease of the spine: evaluation and treatment. Clin Orthop Relat Res 2003; 415: S165-S175
314 Weaver DL, Krag DN, Ashikaga T et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma:
a multicenter study. Cancer 2000; 88: 1099-1107
315 Whelan T, Clark R, Roberts R et al. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent
mortality: results from a randomized trial. Investigators of the Ontario
Clinical Oncology Group. Int J Radiat Oncol Biol Phys 1994; 30: 11-16
316 Whelan T, Darby S, Taylor C et al. Overviews of randomized trials of radiotherapy in early breast cancer. ASCOʼs
Annual Meeting Educational Book. Chicago (USA): ASCO; 2007: 3-6
317 Whelan T, Levine M. Radiation therapy and tamoxifen: concurrent or sequential? That is the
question. J Clin Oncol 2005; 23: 1-4
318 Whelan TJ, Pignol JP, Levine MN et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513-520
319 WHO. World Health Organization Classification of Tumours. Pathology and Genetics of
Tumours of the Breast and female Genital Organs. In: Tavassoli FA, Devilee P, , eds. . Lyon: IARC Press; 2003: 9-112
320 Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline
recommendations for human epidermal growth factor receptor 2 testing in breast
cancer. J Clin Oncol 2007; 25: 118-145
321 Wunder JS, Ferguson PC, Griffin AM et al. Acetabular metastases: planning for reconstruction and review of results. Clin Orthop Relat Res 2003; 415: S187-S197
